恶性疟原虫血症不降低HIV感染者mRNA新冠加强针的中和抗体应答
本研究评估了无症状HIV感染成人在接种单价mRNA-1273或二价mRNA-1273.222加强针后,合并或未合并PCR确诊恶性疟原虫血症者的中和抗体应答。
要点
- ID50=1000与96%预防COVID-19效力相关,本研究中两组滴度均远超该阈值。
- 无症状恶性疟原虫血症不降低HIV感染者mRNA新冠加强针的中和抗体应答。
核心结论
- COVID-19 mRNA疫苗抗体应答不受合并无症状疟原虫血症影响。
研究设计与样本
- 评估无症状HIV感染成人接种单价mRNA-1273或二价mRNA-1273.222加强针后的中和抗体应答,比较PCR确诊合并与未合并恶性疟原虫血症者。
关键数值与推荐
- 既往研究中ID50中和抗体滴度1000与96%预防COVID-19效力相关。
临床怎么用
- HIV感染者合并无症状恶性疟原虫血症时,仍可按计划接种mRNA新冠加强针。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
mRNA vaccines have emerged as powerful tools for the prevention of infectious diseases, but subclinical malaria may reduce vaccine immunogenicity. We evaluated neutralizing antibody responses in asymptomatic HIV-infected adults with and without polymerase chain reaction-confirmed Plasmodium falciparum who received either monovalent mRNA-1273 or bivalent mRNA-1273.222 (WA-1 and BA.4/5) booster vaccines. In previous studies, a 50% pseudovirus inhibitory dose neutralizing antibody (ID50) titer of 1000 correlated with 96% efficacy in preventing COVID-19. We observed ID50 geometric mean titers >22 000 in both parasitemic and nonparasitemic participants 1 month after boosting. We conclude that COVID-19 mRNA vaccine antibody responses are unimpaired by concurrent asymptomatic parasitemia.
引用
- Samandari T, Achola M, Hutter JN, et al. Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults. J Infect Dis. 2025. PMID: 40751436. doi:10.1093/infdis/jiaf398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。